Skip Navigation Links
Front Page
About GNSExpand About GNS
Arts & Culture
Business/Industry
CommunitiesExpand Communities
EducationExpand Education
Entertainment
Links
Maritime
Medical News
Opinion/ForumExpand Opinion/Forum
Public Safety
Transportation
Weather


Medical News
University of Texas Medical Branch
News Release
Wednesday, June 25, 2014

Researchers one step closer to countering deadly Nipah virus
Human antibody therapy successfully combats virus five days after infection

GALVESTON, Texas – An interdisciplinary research team from the University of Texas Medical Branch at Galveston, the Uniformed Services University of the Health Sciences and three groups within the National Institutes of Health reports a new breakthrough in countering the deadly Nipah virus. The human monoclonal antibody known as m102.4 is the first effective antiviral treatment for Nipah that has the potential for human therapeutic applications.

Nipah and the closely related Hendra virus are highly infectious agents that emerged from Pteropid fruit bats in the 1990s, causing serious disease outbreaks in a variety of domestic animals and humans in Australia, Malaysia, Singapore, Bangladesh and India. Recent Nipah outbreaks have resulted in acute respiratory distress syndrome and encephalitis, person-to-person transmission and greater than 90 percent fatality rates among people. These properties make both Nipah and Hendra viruses a concern to human and livestock health.

Previous studies conducted by these researchers have found that the patented m102.4 antibody therapy could protect nonhuman primates from a deadly Hendra infection. In a paper appearing in Science Translational Medicine on June 25, the group describes the human monoclonal antibody therapy that protected nonhuman primates from disease at several time points after Nipah exposure, including the onset of clinical illness in this lethal disease.

“What makes this study unique is that we have achieved complete protection against death even in animals that received treatment five days after being infected with the Nipah virus when they otherwise would have succumbed within 8-10 days of infection,” according to UTMB professor Thomas Geisbert, first author of the paper. “This recent success of the antibody therapy against Nipah virus disease in a nonhuman primate is a key step towards its development as a therapeutic for use in people.”

Christopher Broder, USU professor and Geisbert’s fellow senior author, stated that because of the new data and previous work with this antibody with Hendra virus experiments, “there was sufficient interest for the Queensland government in Australia to initiate a phase I clinical safety trial with m102.4 that is set to commence later this year.”

Other authors of this paper include Chad Mire, Joan Geisbert, Krystle Agans, Karla Fenton and Katharine Bossart from UTMB; Yee-Peng Chan from USU; and Friederike Feldmann, Zhongyu Zhu, Dimiter Dimitrov, Dana Scott and Heinz Feldmann from NIH. This research was supported by the Department of Health and Human Services and the NIH.






Guidry News Service is headquartered in Midtown Houston.
at 4001 Fannin Street, Suite 4432, Houston, TX. 77004-4077
(409) 763 NEWS(6397)         News@GuidryNews.com
© 1996, Guidry News Service. Duplication of any part of this website in any manner is prohibited.